Login
$INAB
$0.75 -$0.07 (8.05%) After hours

$INAB SEC Filings

Filed On Filing
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

13 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 S-8
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half...

01 Jun 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

IN8bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:

01 Jun 2026 424B5
29 May 2026 SCHEDULE 13D/A
29 May 2026 Form 4: Fairbairn Emily, Director

Gave 724,637 shares as a gift

19 May 2026 EFFECT
18 May 2026 S-3/A
15 May 2026 CORRESP
12 May 2026 Form 4: Ho William Tai-Wei, Director

Granted 154,500 Employee Stock Option (right to buy)

12 May 2026 Form 4: Greenwood Luba, Director

Granted 22,000 Stock Option (right to buy)

12 May 2026 Form 4: Lamb Lawrence, EVP and CSO

Granted 54,000 Employee Stock Option (right to buy)

12 May 2026 Form 4: Fairbairn Emily, Director

Granted 22,000 Stock Option (right to buy)

12 May 2026 Form 4: McCall Patrick, CHIEF FINANCIAL OFFICER

Granted 56,250 Employee Stock Option (right to buy)

12 May 2026 Form 4: Rochlin Kate, President and COO

Granted 60,000 Employee Stock Option (right to buy)

12 May 2026 Form 4: Epperly Corinne, Director

Granted 22,000 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support